Captopril-DN
1993
Captopril in Diabetic Nephropathy (Collaborative Study Group)
In 409 patients with type 1 diabetes and diabetic nephropathy, captopril reduced doubling of serum creatinine compared with placebo.
Result
Efficacy: Doubling of baseline serum creatinineHR 0.52 (95% CI 0.31-0.84) · P = 0.007
Below 1 favours captopril, above 1 favours placebo.
Also reported: ~50% reduction in death, dialysis, or transplantation.
- Subtopic
- RAAS blockade
- Design
- Double-blind RCT, median 3-year follow-up
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Lewis EJ, et al. N Engl J Med. 1993;329(20):1456-1462.doi 10.1056/NEJM199311113292004
Discussion & critique
First proof of renoprotection beyond blood-pressure lowering; established ACE inhibitors as standard in type 1 diabetic nephropathy. Limited to T1DM with no blood-pressure-equivalent control arm.